Ernexa Therapeutics (ERNAW) Stock Price, News & Analysis
Company Description
Ernexa Therapeutics (NASDAQ: ERNAW) is classified in the Pharmaceutical Preparations sector.
For FY2025, Ernexa Therapeutics reported net income of -$14.1M and diluted earnings per share of $-2.24.
This page collects what Stock Titan holds for ERNAW, including price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Ernexa Therapeutics (ERNAW) stock last closed at $0.0500.
ERNAW Rankings
Latest News
SEC Filings
Ernexa Therapeutics has filed 5 recent SEC filings, including 3 Form 8-K, 2 Form SCHEDULE 13G/A. The most recent filing was submitted on July 2, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all ERNAW SEC filings →
Financial Highlights
operating income reached -$9.3M, and net income was -$14.1M. Diluted earnings per share stood at $-2.24. The company generated -$7.0M in operating cash flow. With a current ratio of 1.01, the company maintains adequate short-term liquidity.
Upcoming Events
Short Interest History
Short interest in Ernexa Therapeutics (ERNAW) currently stands at 803 shares, down 10.7% from the previous reporting period. Since February 2026, short interest has increased by 301.5%.
Days to Cover History
Days to cover for Ernexa Therapeutics (ERNAW) currently stands at 1.0 days. This low days-to-cover ratio indicates high liquidity, allowing short sellers to quickly exit positions if needed.
ERNAW Company Profile & Sector Positioning
Ernexa Therapeutics (ERNAW) operates in the Pharmaceutical Preparations sector and is listed on the NASDAQ.